论文部分内容阅读
目的检测Her-2基因拷贝量在新辅助化疗(NAC)前后的表达情况,初步探讨化疗药物对预后因子表达的调控。方法采用实时PCR方法检测28例乳腺癌初治患者在接受新辅助化疗后,乳腺癌组织中Her-2基因拷贝量的变化情况。结果新辅助化疗前Her-2基因拷贝量明显高于化疗后,但其Her-2基因拷贝量的改变与病例临床分期和化疗周期数目无关。结论新辅助化疗能使乳腺癌Her-2基因拷贝量减少,下调Her-2基因的表达,提示新辅助化疗也可能通过下调Her-2基因的表达,而改善乳腺癌患者的预后。
Objective To detect the expression of Her-2 gene before and after neoadjuvant chemotherapy (NAC) and to investigate the regulation of the expression of prognostic factors by chemotherapeutics. Methods The real-time PCR method was used to detect the changes of Her-2 gene copy number in 28 cases of breast cancer patients undergoing neoadjuvant chemotherapy. Results The Her-2 gene copy number in neoadjuvant chemotherapy was significantly higher than that after chemotherapy, but the change of Her-2 gene copy number was not related to the clinical stage and the number of chemotherapy cycles. Conclusions Neoadjuvant chemotherapy can reduce the Her-2 gene copy number and down-regulate the expression of Her-2 gene in breast cancer, suggesting that neoadjuvant chemotherapy might improve the prognosis of breast cancer patients by down-regulating the expression of Her-2 gene.